

1 **Title: UDCA and INT-777 suppress cardiac fibrosis triggered by IL-**  
2 **11 through involvement of TGR5**

3

4 **Authors**

5 B. Reilly-O'Donnell<sup>1</sup>, E. Ferraro<sup>1</sup>, R. Tikhomirov<sup>1</sup>, R. Nunez-Toldra<sup>1</sup>, A. Shchendrygina<sup>1</sup>, L.  
6 Patel<sup>1</sup>, Y. Wu<sup>1</sup>, A. L. Mitchell<sup>2</sup>, A. Endo<sup>1</sup>, L. Adorini<sup>3</sup>, R. A. Chowdhury<sup>1</sup>, P. K. Srivastava<sup>1</sup>, F.  
7 S. Ng<sup>1</sup>, C. M. Terracciano<sup>1</sup>, C. Williamson<sup>2</sup> and J. Gorelik<sup>1\*</sup>.

8

9 **Affiliations**

10 <sup>1</sup>National Heart and Lung Institute, Imperial College London, London, United Kingdom.

11 <sup>2</sup>Department of Women and Children's Health, King's College London, London, United  
12 Kingdom.

13 <sup>3</sup>Intercept Pharmaceuticals Inc., New York, USA.

14 \*To whom correspondence should be addressed:

15 [Julia.gorelik@imperial.ac.uk](mailto:Julia.gorelik@imperial.ac.uk)

16 ORCID: 0000-0003-1148-9158.

17 ICTEM, 72 Du Cane Road, London W12 0NN.

18

## 19 Abstract

20 Cardiac fibrosis occurs in a wide range of cardiac diseases and is characterised by the  
21 transdifferentiation of cardiac fibroblasts (FB) into myofibroblasts (MFB). Myofibroblasts  
22 produce large quantities of extracellular matrix proteins, resulting in myocardial scar. The  
23 antifibrotic effect of the bile acid ursodeoxycholic acid (UDCA) is established in cases of liver  
24 fibrosis but not the adult myocardium.

25 Our hypothesis is: UDCA is antifibrotic in the adult heart, mediated by the membrane bile  
26 acid receptor Takeda G protein-coupled receptor 5 (TGR5).

27 We constructed a predictive network of fibrosis using RNA-seq datasets. We found that  
28 UDCA and its analogue INT-777, both reduced MFB markers in rat and human FBs and  
29 living myocardial slices (LMS). Utilising a knock-out mouse model, we show that the  
30 antifibrotic effect of UDCA is mediated by TGR5. Finally, we performed RNA-seq upon  
31 UDCA-treated human FB and integrated with our network of fibrosis, establishing the  
32 mechanism of TGR5 agonists.

33

## 34 Introduction

35 Cardiac fibrosis is a defining feature of maladaptive cardiovascular remodelling which occurs  
36 in a variety of cardiovascular diseases (CVDs) and associated conditions such as; obesity,  
37 diabetes and kidney disease (Boer et al., 2019). The development of a fibrotic scar is  
38 detrimental to myocardial performance; reducing contractility and altering electrical  
39 conduction (Venero et al., 2015; Cojan-Minzat et al., 2020), which can lead to heart failure  
40 (HF). To date, there are no effective anti-fibrotic treatments which are capable of regulating  
41 the fibrotic response. A treatment which targets cardiac fibrosis is therefore an urgent  
42 requirement for both prevention and treatment of heart failure.

43 Besides the reparative fibrosis occurring after direct myocardial injury, the importance of  
44 reactive or interstitial fibrosis in HF pathogenesis has been recognized (Sabbah et al.,  
45 1995). Evolving evidence suggests the contribution of endothelial dysfunction (Huby et al.,  
46 2015), chronic low-grade systemic, and myocardial inflammation to the development of  
47 interstitial cardiac fibrosis (Frantz et al., 2018). In the setting of chronic myocardial  
48 inflammation, activated pro-inflammatory resident macrophages (Frantz et al., 2018) support  
49 the release of pro-inflammatory cytokines and chemokines including transforming growth  
50 factor-beta (TGF- $\beta$ 1), a key regulator of the fibrotic process (Yousefi et al., 2020). Among  
51 the multifactorial pro-inflammatory actions of TGF- $\beta$ 1, it facilitates fibroblast (FBs) activation,  
52 resulting in their transdifferentiation into myofibroblasts, particularly through IL-11  
53 signalling (Schafer et al., 2017; Corden et al., 2020). The appearance of MFBs is a crucial  
54 way-marker in the development of maladaptive myocardial fibrosis (Tarbit et al., 2019). Once  
55 they appear, MFBs persist, contributing to the dysregulation of extracellular matrix (ECM).  
56 MFBs are incredibly active, causing disturbance in the synthesis and degradation of  
57 cytokines, growth factors, and matrix metalloproteinases (MMPs) (Travers et al., 2016).  
58 This leads to excessive ECM component secretion, which facilitates interstitial fibrosis  
59 formation. The conversion of fibroblasts into myofibroblasts therefore represents an  
60 attractive target for anti-fibrotic treatments.

61 Ursodeoxycholic acid (UDCA) (3,7-dihydroxy- 5-cholanic acid), a hydrophilic secondary bile  
62 acid (BA), is commonly used to treat primary biliary cholangitis (Lindor et al., 1994; Cheung  
63 et al., 2016) and intrahepatic cholestasis of pregnancy (Carey and Lindor, 2012; Farooqui et  
64 al., 2022). UDCA has been identified as an agonist of the farnesoid X receptor (Mueller et

65 al., 2015), TGR5 (Ibrahim et al., 2018) and free fatty acid 4 receptors (Xu et al., 2022).  
66 Besides its hepatoprotective, anti-apoptotic (Rodrigues and Steer, 2001; Amaral et al., 2009)  
67 and antioxidant effects (Lapenna et al., 2002), recent findings have demonstrated the anti-  
68 inflammatory (Tanaka et al., 2015; Calmus and Poupon, 1991) and antifibrotic potential of  
69 UDCA in the liver. The effect of BAs upon the heart was first described by Williamson et al.  
70 in 2001, since this initial publication the mechanism of action of BAs upon myocardial tissue  
71 has been extensively investigated (Williamson et al., 2001). UDCA has been identified to  
72 have cardioprotective effects against taurocholic acid-induced arrhythmia (Gorelik et al.,  
73 2004) and to modulate the action potential of cardiomyocytes and myofibroblasts (Schultz et  
74 al., 2016; Miragoli et al., 2011). Several studies have proposed that UDCA and its conjugate  
75 tauroUDCA (TUDCA) may have both anti-inflammatory and anti-fibrotic effects in the  
76 heart (von Haehling et al., 2012; Rani et al., 2017). In a mouse model of left ventricle  
77 pressure overload, induced by transverse aortic constriction (TAC), oral administration of  
78 TUDCA significantly reduced collagen deposition in the myocardium (Rani et al.,  
79 2017). Interestingly, the levels of pro-inflammatory proteins (TGF- $\beta$  and p-Smad3) and  
80 mRNA expression of ECM proteins (Collagen 1 $\alpha$ 1 and 3 $\alpha$ 1) were decreased in the  
81 myocardial tissue of TUDCA-treated mice (Rani et al., 2017). The ability of UDCA to reduce  
82 plasma levels of pro-inflammatory cytokines was also confirmed in a small clinical study (von  
83 Haehling et al., 2012). In HF patients, UDCA treatment was associated with a lower  
84 concentration of soluble tumour necrosis factor  $\alpha$ -receptor 1 (TNF $\alpha$  -1) in plasma, whereas  
85 the concentrations of TNF $\alpha$  and interleukin-6 remained unchanged (von Haehling et al.,  
86 2012). In 2016, for the first time, Schulz et al reported a significant decrease of MFBs in  
87 neonatal rat and human FBs, cultured in hypoxic conditions after UDCA treatment (Schultz  
88 et al., 2016). Recently our group has identified that UDCA, along with many other bile acids,  
89 can cause an increase in intracellular cyclic-AMP in neonatal rat ventricular myocytes  
90 (Ibrahim et al., 2018), this effect was attributed to the activation of the receptor GPBAR1/  
91 TGR5. However, the anti-fibrotic action of UDCA in adult human culture models of cardiac  
92 fibrosis, requires further investigation. Additionally, the mechanism of anti-fibrotic action of  
93 UDCA in the heart requires further exploration.

94 TGR5 is a G-coupled protein coupled membrane receptor which can be activated by BAs, it  
95 is currently being investigated as a potential target for anti-fibrotic treatments (Pols et al.,  
96 2011). Mapping studies indeed indicate that the TGR5 receptor is broadly expressed in  
97 human and animal tissue and organs, including the heart (Kawamata et al., 2003). This is  
98 not limited to cardiomyocytes, TGR5 has been found in endothelial (Keitel et al., 2007) and  
99 immune cells (Perino et al., 2014)— key regulators of the fibrotic process. However, little is  
100 known about TGR5's expression in cardiac fibroblasts. Bile acid activation of TGR5 induces  
101 cyclic adenosine monophosphate (cAMP) production, stimulation of various intracellular  
102 signalling into the cytoplasm such as AKT (Kida et al., 2013; Perino et al.,  
103 2014), extracellular signal-regulated kinases 1 / 2 (Masyuk et al., 2013a), and NF- $\kappa$ B  
104 pathways (Pols et al., 2011; Wang et al., 2011; Yoneno et al., 2013). This leads to  
105 downstream signalling events that contribute to the regulation of basal metabolism,  
106 inflammatory response, and tissue regeneration. Current knowledge suggests that activation  
107 of the TGR5 receptor by the selective agonist INT-777 (Sato et al., 2008) reduces the  
108 expression of pro-inflammatory cytokines including TGF $\beta$ -1 by glomerulus mesangial cells in  
109 kidney (Yang et al., 2016) and decreases renal fibrosis in diabetic mice (Wang et al.,  
110 2016). However, the physiological role of TGR5 receptors in the heart still requires  
111 investigation.

112

113 In this study, we investigated the anti-fibrotic effect of UDCA in human and rat cell culture  
114 models of cardiac fibrosis. We also established the mechanism of action of UDCA in cardiac  
115 FBs isolated from TGR5 KO mice. We utilised human and rat myocardial slices to translate

116 our culture studies into a multi-cellular model. Finally, we used published RNAseq datasets  
117 of healthy and DCM patients to confirm our mechanism of action of TGR5 agonists as a  
118 treatment of cardiac fibrosis.

119

## 120 **Results**

### 121 Prediction of interaction of GPBAR1 with profibrotic network in human DCM FBs.

122 A network of genes differentially expressed due to IL-11 or TGF- $\beta$  treatment of human FBs  
123 was constructed from the RNA-seq datasets published by Schafer et al. (Schafer et al.,  
124 2017) and Chen et al. (Chen et al., 2019). Analysis of the gene ontology enrichment of these  
125 datasets showed a high prevalence of genes clearly associated with cardiac fibrosis, in the  
126 IL-11 (Fig. 1A) and WWP2/ TGF- $\beta$  networks (Fig. 1B). The 'profibrotic' gene network was  
127 combined with known protein- protein interactions of GPBAR1 (the gene encoding TGR5)  
128 (Fig. 1C) to construct a predictive network of the interaction of GPBAR1 / TGR5 with  
129 profibrotic pathways. This provides a comprehensive prediction of how TGR5 interacts with  
130 pro-fibrotic networks.

### 131 RNA-seq analysis reveals antifibrotic pathways associated with TGR5 signalling

132 We performed RNA-seq analysis upon cultured human DCM FBs. Incubation of cells with IL-  
133 11 caused a significant change ( $p$ -value $< 0.05$  or  $-\log_{10}(p\text{-value}) > 1.42$ ) in the expression in  
134 360 genes (Fig. 7A). Pre-treatment of cultures with  $1\mu\text{M}$  UDCA caused a reversal in the  
135 expression patterns (Fig. 7B). A plot of  $\log_{10}$ -fold changes of 109 genes which were  
136 significantly regulated in both IL-11-treated and UDCA-treated conditions (Fig. 7C). The  
137  $\text{Log}(\text{fold change})$  of genes in response to UDCA was mapped (Fig. 7D) onto the predictive  
138 network (established in Fig. 1A). Gene set enrichment analysis showed a reversal of the IL-  
139 11 (Fig. 7E) and WWP2/ TGF- $\beta$  (Fig. 7F) profibrotic pathways (false discovery rate (adjusted  
140  $p$ -value $< 0.05$ )).

141

### 142 UDCA prevents the expression of cardiac fibrosis markers in wild type (WT) rat and human 143 DCM FBs

144 Rat ventricular FBs pre-treated with UDCA for 24hrs, before stimulation by 5ng/ml IL-11,  
145 showed a concentration-dependent decrease in the percentage of  $\alpha$ - smooth muscle actin  
146 ( $\alpha\text{SMA}$ ) positive cells (Fig. 2A). UDCA significantly reduced the percentage of  $\alpha\text{SMA}$  positive  
147 cells from  $57.7 \pm 2.2\%$  to  $35.8 \pm 4.0\%$  when pre-treated with  $10\mu\text{M}$  UDCA (Fig. 2B). The  
148 percentage of  $\alpha\text{SMA}$  positive cells when pre-treated with  $1\mu\text{M}$  UDCA was also significantly  
149 reduced from IL-11 treated controls (Fig. 2B).

150 Similarly, collagen I staining of WT rat FBs was significantly reduced by pre-treatment of  
151 cultures with UDCA (Fig. 2C). Mean cell fluorescence was reduced from  $77.3 \pm 9.0$  to  $51.6$   
152  $\pm 4.1$  when cells were incubated with  $10\mu\text{M}$  UDCA (Fig. 2D). The mean cell fluorescence of  
153 cells pre-treated with 0.1 and  $1\mu\text{M}$  UDCA was also significantly reduced from IL-11 treated  
154 controls; there was no significance between UDCA concentrations tested.

155 Pre-treatment of WT rat FBs with INT-777 significantly reduced the percentage of  $\alpha\text{SMA}$   
156 positive cells in a concentration- dependent manner. Incubation of FBs with  $10\mu\text{M}$  INT-777  
157 significantly reduced the percentage of  $\alpha\text{SMA}$  positive cells from  $61.5 \pm 4.0\%$  to  $9.7 \pm 2.0\%$ ,

158 pre-incubation of cells with 1 $\mu$ M INT-777 also significantly reduced the percentage of  $\alpha$ SMA  
159 positive cells compared to IL-11 treated control (Fig. 2E).

160 Western blot analysis of protein expression in WT rat FBs identified significant reduction in  
161  $\alpha$ SMA (Fig. 2F) and Collagen VI (Fig. 2G) at both 1 $\mu$ M and 10 $\mu$ M. There was no significant  
162 change in Collagen I expression observed by Western blot analysis (Fig. 2H).

163 UDCA reduced the percentage of  $\alpha$ SMA positive human DCM FBs in a concentration-  
164 dependent manner (Fig. 3A). Pre-incubation of cells with either 1 $\mu$ M or 10 $\mu$ M UDCA  
165 significantly reduced  $\alpha$ SMA positive cells from 44.0  $\pm$ 3.0% to 21.7  $\pm$ 2.8% and 16.7  $\pm$ 2.6%  
166 respectively (Fig. 3B). However, we did not observe any significant change in collagen I  
167 staining (Fig. 3C and D).

168 A concentration-dependent decrease of  $\alpha$ SMA positive human DCM FBs was also observed  
169 in response to incubation with INT-777 (Fig. 3E). A significant reduction in  $\alpha$ SMA positive  
170 cells was observed when FBs were incubated with 10 $\mu$ M INT-777 from 44.3  $\pm$ 3.19% to 21.9  
171  $\pm$ 3.3%, both 0.1 $\mu$ M and 1.0 $\mu$ M INT-777 also significantly reduced the percentage of  $\alpha$ SMA  
172 positive cells when compared to IL-11 treated control (Fig. 3E).

173 There was a trend, but no significant reduction, in  $\alpha$ SMA expression of human DCM FBs  
174 pre-treated with UDCA or INT-777 at any concentration tested, when assessed by Western  
175 blot analysis (Fig. 3F). However, Collagen I expression was significantly reduced following  
176 treatment with 10 $\mu$ M UDCA (Fig. 3G).

#### 177 UDCA reduces fibrosis markers and improves contractility of WT rat living myocardial slices

178 Rat living myocardial slices were produced and cultured with electrical stimulation for 48hrs  
179 using established methods (Perbellini et al., 2018; Watson et al., 2017; Pitoulis et al., 2020)  
180 and then stained for Collagen I (Fig. 4A) and assessed by percentage area stained (Fig. 4B).  
181 Incubation of rat slices with 10ng/ml IL-11 significantly increased the percentage area of  
182 Collagen I compared to untreated control slices from 12.4  $\pm$ 0.9% to 16.0  $\pm$ 0.9. Co-treatment  
183 of slices with 10 $\mu$ M UDCA and IL-11 significantly reduced the percentage area of Collagen I  
184 from 16.0  $\pm$ 0.9 to 9.7  $\pm$ 0.9%. Incubation of slices with UDCA alone had no significant effect  
185 upon the area of collagen I staining, although there is a trend to a reduced area of staining  
186 (9.3  $\pm$ 0.5%). The reduction of collagen I staining was also reflected by Western blot (Fig.  
187 4C), where co-treatment of slices with 10 $\mu$ M UDCA and IL-11 reduced the expression of  
188 collagen I. The functionality of live rat LMS was assessed by a force- transducer with pacing  
189 at 1Hz (Fig. 4D). Maximal contractility of slices was reduced by IL-11 from 3.8  $\pm$ 0. mN/mm<sup>2</sup>  
190 to 1.3  $\pm$ 0.2 mN/mm<sup>2</sup>. Co-incubation of the slice with 10 $\mu$ M UDCA and IL-11 improved  
191 maximal contractility from 1.3  $\pm$ 0.2 mN/mm<sup>2</sup> to 3.8  $\pm$ 0.3 mN/mm<sup>2</sup> (Fig. 4E). Co-treatment of  
192 slices with 10 $\mu$ M UDCA and IL-11 reduced the half-width of contractions from 244.5  $\pm$ 7.4ms  
193 to 160.6  $\pm$ 9.9ms (Fig. 4F).

#### 194 UDCA reduces markers of fibrosis in human DCM living myocardial slices

195 The percentage area of collagen I staining in human LMS was significantly higher in human  
196 DCM slices compared to donor (18.5  $\pm$ 1.1% vs. 11.3  $\pm$ 1.4%) (Fig. 5A and B). "Donor" slices  
197 were produced from organ donor non-failing hearts not suitable for transplantation.  
198 Treatment of human DCM LMS with 10 $\mu$ M UDCA for 48hrs significantly reduced the  
199 percentage collagen area from 18.5  $\pm$ 1.1% to 13.5  $\pm$ 0.8% (Fig. 5A and B). The contractility of  
200 slices was also assessed (Fig. 5C), LMS prepared from DCM hearts had very low  
201 contractility (9.7  $\pm$ 2.7% of donor LMS contractility). The relative contractility of human DCM  
202 slices was slightly increased when slices were treated with 10 $\mu$ M UDCA for 48hrs (12.9  
203  $\pm$ 3.9% vs. 9.7  $\pm$ 2.7% of donor LMS contractility), however this was not significant (Fig. 5D).

204 Knock-out of TGR5 reduces the anti-fibrotic effect of UDCA in mouse fibroblasts

205 Incubation of WT mouse FBs with 1 $\mu$ M and 10 $\mu$ M UDCA significantly reduced the  
206 percentage of  $\alpha$ SMA positive cells from 56.6  $\pm$ 8.5% to 30.4  $\pm$ 7.9% and 22.9  $\pm$ 2.3%  
207 respectively (Fig. 6A and B). There was no significant reduction of  $\alpha$ SMA positive cells in  
208 TGR5 KO FBs, when pre-treated with 1 or 10 $\mu$ M UDCA (Fig. 6B). Mean cell fluorescence of  
209 both WT and TGR5 KO FBs stained for collagen I was reduced in both cell types when  
210 incubated with 10 $\mu$ M UDCA (Fig. 6C). The TGR5-specific agonist, INT-777, also caused a  
211 reduction in the percentage of  $\alpha$ SMA expressing WT FBs. This effect of INT-777 was lost in  
212 TGR5 KO FBs (Fig. 6D). Western blot analysis of  $\alpha$ SMA expression reflected the findings of  
213 our imaging experiments (Fig. 6E). There was no change in total ERK1/2 expression in any  
214 conditions examined (Fig. 6F). Analysis of ERK1/2 phosphorylation in WT mouse FBs  
215 identified that pre-treatment of WT FBs with 1 $\mu$ M UDCA significantly reduced  
216 phosphorylation (relative density was reduced from 1.3  $\pm$ 0.1 to 1.0  $\pm$ 0.1) (Fig. 6G). This  
217 reduction in ERK1/2 phosphorylation by UDCA was lost in TGR5 KO FBs (Fig. 6G).

218

219 **Discussion**

220 Using multiple models of cardiac fibrosis, we have demonstrated the antifibrotic effect of the  
221 TGR5 agonists UDCA and INT-777. We have characterised the interaction of the pro-fibrotic  
222 network with TGR5 and suggest that UDCA and other TGR5 agonists have the potential to  
223 reduce cardiac fibrosis.

224 Antifibrotic effect of bile acids in adult rat models of cardiac fibrosis.

225 The antifibrotic effect of UDCA and INT-777 in cultured adult rat FB was identified by  
226 immunostaining and Western blot. UDCA induced a significant reduction in  $\alpha$ -SMA staining  
227 (Fig. 2B) which was reflected in Western blots (Fig. 2F). This was not the case for Collagen  
228 I, where staining was significantly reduced by UDCA (Fig. 2C and D) but not paralleled in  
229 Western blot (Fig. 2H). Interestingly, we were able to detect a reduction in the anchoring  
230 collagen type VI by Western blot analysis when cells were pre-treated with UDCA (Fig. 2G).  
231 These data taken together indicate that pre-treatment of cultures with UDCA before  
232 stimulation with IL-11 prevents the activation of FB and therefore the emergence of MFB in  
233 cultures. We also found that the TGR5- specific agonist, INT-777 (Pellicciari et al., 2009),  
234 reduced the number of  $\alpha$ -SMA positive cells (Fig. 2E) to an even greater extent than UDCA,  
235 indicating that it too can prevent the transdifferentiation of FB into MFB. This correlates with  
236 similar experiments investigating liver fibrosis, suggesting a common mechanism of action  
237 (Ye et al., 2020).

238 Transferring these cell culture experiments to multi-cellular and hetero-cellular LMS, we  
239 found that collagen I staining was reduced in slices treated with 10 $\mu$ M UDCA (Fig. 4A-C).  
240 This reduction of collagen I is indicative of a reduction of extracellular matrix particularly with  
241 interstitial fibrosis, rather than focal fibrosis. Assessment of the function of the LMS was  
242 determined by force transducer, there was a clear reduction in contractility of the slice when  
243 treated with IL-11 alone, but co-treatment with 10 $\mu$ M UDCA significantly increased function  
244 (Fig. 4E and F). The reduction in contractile dynamics of UDCA-only treated slices,  
245 compared to control, perhaps points towards some non-fibroblast mediated effects of UDCA  
246 (Fig. 4F). It is known that UDCA cannot influence contractility in neonatal mouse myocytes  
247 despite promoting cAMP release (Ibrahim et al., 2018) although there is clear evidence that  
248 UDCA can influence electrophysiological properties of the heart, and reduce ischaemia-  
249 induced arrhythmias (Ferraro et al., 2020; Miragoli et al., 2011; Schultz et al., 2016; Gorelik et  
250 al., 2003). In our recent publication, this was attributed to increased phosphorylation of

251 connexin-43 proteins (Ferraro et al., 2020), which perhaps explains the increased  
252 contraction dynamics of slices treated with UDCA.

### 253 Antifibrotic effect of bile acids in human models of cardiac fibrosis.

254 UDCA was found to inhibit the transdifferentiation of human FB into MFB (Fig. 3).  
255 Interestingly, unlike adult rat FB, there was a significant reduction in collagen I when  
256 assessed by Western blot but not immunostaining. There was a clear reduction in the  
257 number of MFBs in cultures treated with INT-777 (Fig. 3E), indicating that the antifibrotic  
258 action of the bile acids are mediated by TGR5.

259 Treatment of human failing (DCM) slices with UDCA significantly reduced the expression of  
260 collagen I (Fig. 5A and B), indicating that UDCA is antifibrotic in human slices as well as  
261 cultured FB. The reduction of collagen I in slices did not result in a significant increase in  
262 slice contractility (Fig. 5D). This is perhaps due to the samples available; cardiac tissue used  
263 to produce LMS is at an end stage of heart failure and so there is a reduction in the number  
264 of and function of myocytes in the slice. One may expect that reduced cardiac fibrosis will,  
265 however, result in improved diastolic function, countering the dysfunction caused by fibrosis  
266 (Moreo et al., 2009), further studies utilising LMS would be particularly useful in investigating  
267 this phenomenon. This indicates that any future treatments of heart failure involving bile  
268 acids would require administration early in the pathogenesis of heart failure if contractile  
269 function is to be maintained.

### 270 TGR5 is required to prevent transdifferentiation of fibroblasts into myofibroblasts

271 The antifibrotic effect of UDCA was observed in WT mouse FB (Fig. 6) but was lost in TGR5  
272 KO cultures. This agrees with our pharmacological study in which INT-777, the TGR5-  
273 specific agonist, prevented the expression of MFB markers (Fig. 2E, 3E). Our lab has  
274 previously identified that UDCA can stimulate cAMP release via TGR5 in neonatal rat  
275 myocytes (Ibrahim et al., 2018) and that unconjugated UDCA is more potent than tauro- or  
276 glyco- conjugated UDCA. Along with the present data we propose TGR5 activation as the  
277 mechanism of action of both UDCA and INT-777 in the inhibition of cardiac fibrosis.  
278 Interestingly, we found that UDCA significantly reduced the phosphorylation (but not  
279 expression) of ERK1/2 in WT, but not in TGR5 KO FB (Fig. 6F and G), identifying a  
280 downstream signalling of TGR5 in cardiac FB similar to ciliated cholangiocytes (Masyuk et  
281 al., 2013b).

### 282 Role of TGR5 signalling in cardiac fibrosis

283 A gene expression network was constructed from published RNA-seq data (Schafer et al.,  
284 2017) and known TGR5 (GPBAR-1) interactors. In this network we identified genes  
285 regulated in pro-fibrotic conditions (stimulated by IL-11) and arranged them by their shortest  
286 path connectedness to TGR5/ GPBAR-1, three layers of the network are presented (Fig.  
287 1C). Analysis of the previously published RNA-seq datasets using gene ontology  
288 annotations (DAVID) found a number of pathways expected to be activated in FB during  
289 proliferative fibrosis were indeed upregulated i.e. cell migration, cell proliferation, MAP  
290 kinase pathway, TGF- $\beta$  signalling (Fig. 1A and B).

291 After performing our own RNA-seq experiments upon human DCM FB we found a number of  
292 genes to be significantly up- and down- regulated when cultures were stimulated with IL-11  
293 (Fig. 7A). Interestingly pre-treatment of cultures with 1 $\mu$ M UDCA before stimulation with IL-  
294 11 caused an almost exact reversal of the gene expression profile (Fig. 7B), as noted by the  
295 scatter plot of significantly regulated genes in both conditions (Fig. 7C). Gene-set enrichment  
296 analysis, against the published IL-11 and WWP2/ TGF- $\beta$  datasets showed that IL-11

297 enriched the profibrotic network and UDCA reversed this effect (Fig. 7D and E). Mapping  
298 our own experimental data onto our network (Fig. 7F) reveals the interaction of both the pro-  
299 fibrotic and anti-fibrotic pathways investigated in this study.

300 This study confirms the potential of UDCA and INT-777 as treatments of cardiac fibrosis in  
301 the adult myocardium. Using multiple animal and human models, we have identified that  
302 TGR5 agonists can prevent the transdifferentiation of FB into MFB and have characterised  
303 the gene expression network associated with the pro- and anti- fibrotic pathways.

304

### 305 Ideas and speculation

306 Currently there are no drugs approved primarily for the treatment of cardiac fibrosis, despite  
307 a broad range of strategies investigated (Sweeney et al., 2020). Although inhibitors of the  
308 renin-angiotensin-aldosterone system have been shown to have beneficial effects on  
309 interstitial fibrosis, their effects are modest (Brilla et al., 2000). The repurposing of UDCA is  
310 safely prescribed in the treatment of primary biliary cholangitis (Parés et al., 2006) and  
311 intrahepatic cholestasis of pregnancy (Ovadia et al., 2021), would be of clinical value as an  
312 antifibrotic agent. There is already mounting evidence that TGR5 agonists are beneficial in  
313 patients with heart failure (von Haehling et al., 2012), ischaemia- induced arrhythmia in rat  
314 (Ferraro et al., 2020) and TAC mice (Eblimit et al., 2018). What is unclear is how the non-  
315 fibroblast-mediated effects of TGR5 signalling may affect the long-term function of the heart  
316 and other organs. Unfortunately, TGR5 is widely expressed and so direct activation of the  
317 receptor may not represent a realistic drug target for cardiac fibrosis. The gene network  
318 produced as part of this study (Fig. 1C) may provide new targets which are more suited to a  
319 heart-specific treatment of cardiac fibrosis. Promisingly, there were no adverse events  
320 reported during two-week administration of UDCA in adult rats (Ferraro et al., 2020) or to  
321 patients for 4 weeks (von Haehling et al., 2012). Von Haehling et al. showed that  
322 administration of UDCA can increase peripheral blood flow (von Haehling et al., 2012),  
323 however there was no indication if this was due to improvement of cardiac function or  
324 peripheral vasculature. Another avenue would be to develop the TGR5-specific agonist INT-  
325 777 (over UDCA) as an anti-fibrotic agent, removing the potential 'off-target' effects of  
326 UDCA, for the treatment of cardiac fibrosis and perhaps administer this to patients with  
327 increased risk of developing fibrosis. Reducing cardiac fibrosis will likely have the benefits of  
328 improving diastolic function (Khalil et al., 2017) and also reducing the incidence of ventricular  
329 arrhythmias (Pahor et al., 1991), which accounts for a substantial proportion of deaths in  
330 patients with heart failure (Moss et al., 2002). To further understand the potential of TGR5  
331 agonists as treatments of cardiac fibrosis there is a need to investigate these drugs in  
332 patients.

333

### 334 **Materials and methods**

335 All reagents, unless stated, were purchased from Sigma- Aldrich (Dorset, UK).

336 INT-777 was provided by Intercept Pharmaceuticals, Inc. (New York, USA).

### 337 Isolation and culture of rat and mouse cardiac fibroblasts

338 All animal experiments were performed in the United Kingdom (UK) according to the  
339 standards for the care and use of animal subjects determined by the UK Home Office  
340 (ASPA1986 Amendments Regulations 2012) incorporating the EU directive 2010/63/EU. The

341 animal welfare and ethical review body committee of Imperial College London approved all  
342 protocols.

343 Rat (male, Sprague Dawley) and mouse (male, C57BL/6, WT and TGR5 KO) FBs were  
344 isolated by enzymatic digestion of ventricular tissue as previously described (Wright et al.,  
345 2018). FBs were found in the supernatant after centrifugal pelleting of cardiomyocytes and  
346 were cultured for no more than 20 days before cell fixation/ lysis.

347 Rat FBs were cultured in Dulbecco's modified Eagle's media (DMEM) supplemented with  
348 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution, whereas mouse FBs  
349 were cultured in DMEM supplemented with 20% FBS and 1% antibiotic-antimycotic, at 37°C  
350 and 5% CO<sub>2</sub>.

351 Cultures were pre-treated for 24 hrs with UDCA or INT-777 before stimulation with 5ng/ml IL-  
352 11 (Rat; RPA057Ra01 (Caltag Med systems), Mouse; Z03052 (Genscript)) for a further 24  
353 hrs.

#### 354 Isolation and culture of Human DCM fibroblasts

355 This study was supported by the supply of human failing hearts from the Cardiovascular  
356 Research Centre Biobank, at the Royal Brompton and Harefield hospitals (NRES Ethics  
357 number for biobank samples: 09/H0504/104+5, Biobank approval number: NP001-06-2015  
358 and MED\_CT\_17\_079) and donor hearts from NHS Blood and Transplant (NRES Ethics  
359 number 16/LO/1568, NHS Blood and Transplant study numbers 67 and 106). All procedures  
360 described were carried out in accordance with the Human Tissue Act 2004.

361 Left ventricular free-wall tissue was minced into small chunks (3mm x 3mm x 3mm) and then  
362 lightly digested in 0.05% Trypsin-EDTA for 2 min. Tissue chunks were then transferred into  
363 fibronectin-coated dishes and cultured in DMEM supplemented with 20% FBS and 1%  
364 antibiotic-antimycotic at 37°C and 5% CO<sub>2</sub>. When confluent, FB were harvested from the  
365 dishes and used for experiments.

366 Cultures were pre-treated for 24 hrs with UDCA or INT-777 before stimulation with 5ng/ml IL-  
367 11 (PHC0115, Life Technologies) for a further 24 hrs.

#### 368 Preparation and physiological monitoring of living myocardial slices

369 Living myocardial slices (LMS) were obtained from rat and human tissue, prepared and  
370 cultured in line with previous publications (Watson et al., 2017; Perbellini et al., 2018;  
371 Watson et al., 2019). Sprague-Dawley rats (300-350g) were anaesthetised by inhalation of  
372 4% isoflurane at 4 L/min oxygen and then sacrificed by cervical dislocation. The heart was  
373 removed from the thoracic cavity and placed in ice- cold Tyrode's slice solution (30 mM 2, 3-  
374 Butanedione Monoxime, 140 mM NaCl, 9 mM KCl, 10 mM Glucose, 10 mM HEPES, 1 mM  
375 MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, pH=7.4).

376 A 1.5 cm<sup>2</sup> tissue block was dissected from the free wall of the left ventricle and, using a high  
377 precision vibratome (7000smz-2, Campden Instruments), 300µm thick LMS were prepared.  
378 The LMS were attached to custom-made 3D printed t-glass rectangular rings and then  
379 mounted on metallic stretchers which allow for the setting of diastolic load. In this study the  
380 LMS were cultured at physiological sarcomere length (SL)= 2.2 µm. LMS were placed inside  
381 sterile culture chambers and maintained in circulating, oxygenated media at 37°C for 48 hrs,  
382 under continuous electrical stimulation via carbon electrodes. Rat slices were paced at 1Hz  
383 (width 10ms, 15V) whereas human slices were paced at 0.5Hz (width 10ms, 15V). 10ng/ml

384 recombinant rat IL-11 (Cloud-clone, USA) was used to induce the fibrotic phenotype, either  
385 in the absence or presence of 1 $\mu$ M UDCA.

386 LMS contractility was assessed using a force transducer (Harvard Apparatus, USA). After  
387 48-hours in culture, LMS were connected to a force transducer, field stimulated, and  
388 progressively stretched in a stepwise manner, until the maximum isometric contraction was  
389 obtained. During contractility measurements LMS were perfused with oxygenated Tyrode's  
390 solution at 37 °C. Recordings were obtained using AxoScope software and peak amplitude  
391 analysis conducted using Clampfit software (both Molecular Devices, USA).

#### 392 Western blot

393 Cell lysates were prepared in RIPA buffer supplemented with protease inhibitor cocktail and  
394 phosphatase inhibitor. Tissue lysates were snap frozen and then homogenised in SB-20  
395 lysis buffer.

396 Samples were loaded on 8- 10% polyacrylamide gels and ran at 100V for 1 hr. Proteins  
397 were transferred to PVDF membrane via semi dry transfer (Trans-Blot Turbo, Bio-Rad) or  
398 wet transfer at 100V for 1hr. Membranes were blocked with 5% (w/v) skimmed milk powder  
399 and then incubated with primary antibodies overnight (see figure legend). Secondary  
400 antibodies were either alexa-flour or HRP conjugated (see figure legend) and incubated with  
401 the membrane for 3 hrs. Blots were developed and/ or imaged using a Bio-Rad ChemiDoc  
402 MP.

#### 403 Immunostaining of isolated fibroblasts

404 Cells were cultured on glass coverslips. After the completion of experimental protocol, cells  
405 were fixed with 4% (v/v) PFA for 15 min on ice. Cells were permeabilised with 0.05% (v/v)  
406 Triton X-100 for 15 min and then blocked for 1 hr in 5% (w/v) BSA. Coverslips were  
407 incubated with primary antibody overnight, afterwards the coverslips were transferred into  
408 the appropriate secondary antibody- containing solutions for 1 hr. Coverslips were then  
409 mounted onto glass slides with ProLong Gold antifade mountant with DAPI.

410 Images were captured using either a Zeiss LSM-780 inverted confocal laser scanning  
411 microscope or Nikon Eclipse Ti with pE-4000 light source (Cool LED) and ORCA-Flash 4  
412 camera (Hamamatsu). Imaging was assisted by the Facility for Imaging by Light Microscopy  
413 (FILM) at Imperial College London. FILM is part-supported by funding from the Wellcome  
414 Trust (grant 104931/Z/14/Z) and BBSRC (grant BB/L015129/1). Images were analysed with  
415 Fiji/ ImageJ.

#### 416 Immunostaining of living myocardial slices

417 LMS were washed in PBS and then fixed in 4% PFA. Slices were permeabilised with 1%  
418 Triton X-100 in blocking solution (10% fetal bovine serum, 5% bovine serum albumin and  
419 10% horse serum in PBS) for 3 hrs at room temperature. Primary antibodies were diluted in  
420 PBS and incubated overnight at 4°C. Slices were washed in PBS three times (30 min) and  
421 then incubated with secondary antibodies for 2 hrs at room temperature. Finally, slices were  
422 incubated with Hoechst for 15 min and then stored in PBS at 4 °C. Immunostained slices  
423 were observed using a Zeiss LSM-780 inverted confocal laser scanning microscope. Images  
424 were analysed with Fiji/ ImageJ.

#### 425 Bioinformatic analysis of Human RNA-seq data

426 The data set was obtained from the open source GEO dataset: GSE97358, which was  
427 published through the research of Schafer et al. (Schafer et al., 2017) and GSE133017  
428 which was published through the research of Chen et al. (Chen et al., 2019). This expression  
429 data set consists of RNA-sequencing in 168 primary cardiac FB derived from patients (84  
430 control samples and 84 treated with TGF- $\beta$ ). The data set consisted of 64254 genes and  
431 was uploaded to R (v4.0.2) and then transformed into expression data using the edgeR  
432 package (Robinson et al., 2010). The resulting matrix was filtered to remove minimally-  
433 expressed genes. Genes with a  $\log_{10}(\text{expression})$  value less than 0 in at least 90% (>74) of  
434 all samples were removed. The resulting dataset contained 14203 genes. The filtered  
435 dataset was then separated by culture conditions (control and TGF- $\beta$  treated). Using the  
436 'gtools' package we were able to compare (TGF- $\beta$  treated vs. control) the expression fold  
437 change of all expressed genes in the 84 paired samples (Warnes et al., 2015). The average  
438 expression fold change of each gene was then calculated ( $\log_2(\text{expression fold change})$ )  
439 and applied to the network described below (all NaN and Inf values were replaced with 0).  
440 We then created a correlation matrix of genes which will include; correlation coefficients, p-  
441 values and false discovery rate (FDR) using the Hmisc package (Harrell FE and Dupont,  
442 2007). We extracted a list of 14203 genes and their correlation data for the IL11 gene  
443 (Supplementary data 1A) and then removed matches with FDR greater than 0.05  
444 (Supplementary data 1B), resulting in 4853 genes with significant adjusted p-values. To  
445 further filter our data, we applied another threshold based upon correlation coefficients  
446 (where  $r \geq \pm 0.5$ ) (Supplementary data 1C), in this dataset values varied between -0.78 and  
447 +0.75. The majority of our results were observed to have a low to moderate correlation. For  
448 this reason, we applied a cut off for values with a low correlation value. We considered  
449 values  $\geq \pm 0.5$  to have a strong correlation (Mukaka, 2012). This analysis identified 677  
450 genes which were used to build a protein-protein network. In order to cover other fibrotic  
451 related genes we united our IL-11 co-expression network with a recently constructed WWP2  
452 network (683 genes), from cluster of genes which was found to be important in fibrosis and  
453 responsible for cell adhesion (Chen et al., 2019).

#### 454 Gene set enrichment analysis

455 In order to reveal the enriched pathways associated with the IL-11 co-expression network,  
456 we conducted gene set enrichment analysis using DAVID 6.8 (Huang et al., 2009b; a).  
457 Ensemble gene ids were uploaded as a gene list for Homo Sapiens with the same  
458 background. For each gene, we searched the database annotations for Gene Ontology,  
459 GO\_BP\_Direct and in Pathways, KEGG\_Pathway. We set up the database to only highlight  
460 terms with  $p\text{-value} < 0.05$  (FDR and fold enrichment were also included added as additional  
461 search terms). From this we produced an IL-11 co-expression network (Supplementary data  
462 2).

#### 463 Protein-protein interaction network construction

464 In this study, we aim to construct a protein- protein interaction network based upon genes  
465 identified from the IL-11 co-expression network, we also included GPBAR1, which encodes  
466 for the bile acid receptor TGR5. To construct this network we used STRING v.11 ('Search  
467 Tool for Retrieval of Interacting Genes/Proteins') (Szklarczyk et al., 2019) which links  
468 proteins based on reported associations between them. In order to establish protein  
469 associations, we investigated 7 active interaction sources: textmining, experiments,  
470 databases, co-expression, neighbourhood, gene fusion and co-occurrence. Each edge was  
471 then ranked based upon the confidence of the protein- protein association being true. During  
472 the construction of our protein-protein network, we searched all 7 active sources and only  
473 included pairs of genes which showed greater than 'medium' confidence behind their  
474 association (confidence > 0.4). The resulting network was exported as a table

475 (Supplementary data 3), genes were assigned the average log<sub>2</sub> (expression fold change)  
476 from filtrated IL-11 dataset.

#### 477 Network analysis with Cytoscape 3\_7\_1

478 The network which was generated in STRING v.11 was imported in Cytoscape 3\_7\_1 to  
479 generate a network visualization graph (Shannon, 2003) network analysis was performed  
480 using NetworkAnalyzer (Assenov et al., 2008). In the resulting network graph (Fig. 6A), node  
481 colour represents the average Log<sub>2</sub>(expression fold change) in UDCA vs IL-11 conditions.  
482 The size of each node represents the degree of connectivity (i.e. the number connections  
483 with other elements of a network). We also identified how GPBAR1 interacts with our  
484 combined fibrotic network using the Cytoscape App Pesca3.0.8. This app analyses shortest  
485 path from one node (i.e. GPBAR1) to any other element of a network and can be used to  
486 determine shortest path between two nodes (Scardoni et al., 2016). We finally classified path  
487 lengths as first or second level neighbours of GPBAR1 in order to identify how TGR5 and its  
488 downstream signalling can attenuate cardiac fibrosis. In order to examine how IL-11 or  
489 UDCA treatment affected our resulting network we did enrichment analysis of the network  
490 with WebGestalt. The IL-11 and WWP2/ TGF-β networks were uploaded separately.  
491 Following this we tested the networks with gene lists comparing the IL-11 vs. Control and  
492 UDCA vs. IL-11 conditions (Fig. 7D and E). Significantly regulated genes were defined as  
493 having a false discovery rate <0.05.

#### 494 Statistical analysis of experimental data

495 Data is presented in text as mean ±SEM. Bar charts are presented as mean and SEM of  
496 each experimental group. Statistical significance of experiments, unless stated, was  
497 determined by one-way ANOVA with Tukey's post-hoc test. Levels of significance were; \*p<  
498 0.05, \*\*p< 0.01, \*\*\*p< 0.001. n= number of experiments, N= number of animals/ patients. All  
499 experiments were completed in the same laboratory.

500 Statistical methods used in the bioinformatic analysis of human RNA-seq data are detailed in  
501 the methods above.

#### 502 Data availability statement

503 The authors confirm that the data supporting the findings of this study are available within  
504 the article and its supplementary materials.

505

#### 506 **Supplemental material**

507 Supplementary data 1: IL-11 differential co-expression network construction.

508 Supplementary data 2: Enrichment analysis for IL-11 and WWP2/ TGF- β differentially co-  
509 expressed network.

510 Supplementary data 3: Protein –protein interaction network for IL-11 and WWP2/ TGF- β co-  
511 expressed genes.

512 Supplementary data 4: Raw data

513

## 514 Acknowledgments

515 We wish to thank Mr. Peter O’Gara for his isolation of rat fibroblasts. We thank Kristina  
516 Schoonjans for the donation of the TGR5 KO mouse colony. We thank the patients and  
517 families for the kind donation of human samples.

518 This research was funded by Heart Research UK (RG2666/17/19). RC was funded by the  
519 BHF project grant PG/16/17/32069.

## 520 Competing interests

521 Dr Luciano Adorini is a consultant for Intercept Pharmaceuticals.

522 All other authors declare no conflict of interest.

523

## 524 References

525 Amaral, J.D., R.J.S. Viana, R.M. Ramalho, C.J. Steer, and C.M.P. Rodrigues. 2009. Bile  
526 acids: Regulation of apoptosis by ursodeoxycholic acid. *Journal of Lipid Research*.  
527 50:1721–1734. doi:10.1194/jlr.R900011-JLR200.

528 Assenov, Y., F. Ramírez, S.-E. Schelhorn, T. Lengauer, and M. Albrecht. 2008. Computing  
529 topological parameters of biological networks. *Bioinformatics*. 24:282–284.  
530 doi:10.1093/bioinformatics/btm554.

531 Boer, R.A., W.C. Meijers, P. Meer, and D.J. Veldhuisen. 2019. Cancer and heart disease:  
532 associations and relations. *European Journal of Heart Failure*. 21:1515–1525.  
533 doi:10.1002/ejhf.1539.

534 Brilla, C.G., R.C. Funck, and H. Rupp. 2000. Lisinopril-Mediated Regression of Myocardial  
535 Fibrosis in Patients With Hypertensive Heart Disease. *Circulation*. 102:1388–1393.  
536 doi:10.1161/01.CIR.102.12.1388.

537 Calmus, Y., and R. Poupon. 1991. Ursodeoxycholic acid (UDCA) in the treatment of chronic  
538 cholestatic diseases. *Biochimie*. 73:1335–1338. doi:10.1016/0300-9084(91)90098-L.

539 Carey, E.J., and K.D. Lindor. 2012. Current pharmacotherapy for cholestatic liver disease.  
540 *Expert Opinion on Pharmacotherapy*. 13:2473–2484.  
541 doi:10.1517/14656566.2012.736491.

542 Chen, H., A. Moreno-Moral, F. Pesce, N. Devapragash, M. Mancini, E.L. Heng, M. Rotival,  
543 P.K. Srivastava, N. Harmston, K. Shkura, O.J.L. Rackham, W.-P. Yu, X.-M. Sun, N.G.Z.  
544 Tee, E.L.S. Tan, P.J.R. Barton, L.E. Felkin, E. Lara-Pezzi, G. Angelini, C. Beltrami, M.  
545 Pravenec, S. Schafer, L. Bottolo, N. Hubner, C. Emanuelli, S.A. Cook, and E. Petretto.  
546 2019. WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling.  
547 *Nature Communications*. 10:3616. doi:10.1038/s41467-019-11551-9.

548 Cheung, A.C., L. Lapointe-Shaw, M. Kowgier, J. Meza-Cardona, G.M. Hirschfield, H.L.A.  
549 Janssen, and J.J. Feld. 2016. Combined ursodeoxycholic acid (UDCA) and fenofibrate  
550 in primary biliary cholangitis patients with incomplete UDCA response may improve

- 551 outcomes. *Alimentary Pharmacology & Therapeutics*. 43:283–293.  
552 doi:10.1111/apt.13465.
- 553 Cojan-Minzat, B.O., A. Zlibut, and L. Agoston-Coldea. 2020. Non-ischemic dilated  
554 cardiomyopathy and cardiac fibrosis. *Heart Failure Reviews*. 1–21. doi:10.1007/s10741-  
555 020-09940-0.
- 556 Corden, B., E. Adami, M. Sweeney, S. Schafer, and S.A. Cook. 2020. IL-11 in cardiac and  
557 renal fibrosis: Late to the party but a central player. *British Journal of Pharmacology*.  
558 177:1695. doi:10.1111/BPH.15013.
- 559 Eblimit, Z., S. Thevananther, S.J. Karpen, H. Taegtmeier, D.D. Moore, L. Adorini, D.J.  
560 Penny, and M.S. Desai. 2018. TGR5 activation induces cytoprotective changes in the  
561 heart and improves myocardial adaptability to physiologic, inotropic, and pressure-  
562 induced stress in mice. *Cardiovascular Therapeutics*. 36:e12462. doi:10.1111/1755-  
563 5922.12462.
- 564 Farooqui, N., A. Elhence, and Shalimar. 2022. A Current Understanding of Bile Acids in  
565 Chronic Liver Disease. *Journal of clinical and experimental hepatology*. 12.  
566 doi:10.1016/J.JCEH.2021.08.017.
- 567 Ferraro, E., L. Pozhidaeva, D.S. Pitcher, C. Mansfield, J.H.B. Koh, C. Williamson, O.  
568 Aslanidi, J. Gorelik, and F.S. Ng. 2020. Prolonged ursodeoxycholic acid administration  
569 reduces acute ischaemia-induced arrhythmias in adult rat hearts. *Scientific Reports*.  
570 10:15284. doi:10.1038/s41598-020-72016-4.
- 571 Frantz, S., I. Falcao-Pires, J.-L. Balligand, J. Bauersachs, D. Brutsaert, M. Ciccarelli, D.  
572 Dawson, L.J. de Windt, M. Giacca, N. Hamdani, D. Hilfiker-Kleiner, E. Hirsch, A. Leite-  
573 Moreira, M. Mayr, T. Thum, C.G. Tocchetti, J. van der Velden, G. Varricchi, and S.  
574 Heymans. 2018. The innate immune system in chronic cardiomyopathy: a European  
575 Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial  
576 Function of the ESC. *European Journal of Heart Failure*. 20:445–459.  
577 doi:10.1002/ejhf.1138.
- 578 Gorelik, J., A. Shevchuk, M. Swiet, M. Lab, Y. Korchev, and C. Williamson. 2004.  
579 Comparison of the arrhythmogenic effects of tauro- and glycoconjugates of cholic acid  
580 in an in vitro study of rat cardiomyocytes. *BJOG: An International Journal of Obstetrics  
581 and Gynaecology*. 111:867–870. doi:10.1111/j.1471-0528.2004.00166.x.
- 582 Gorelik, J., A.I. Shevchuk, I. Diakonov, M. Swiet, M. Lab, Y. Korchev, and C. Williamson.  
583 2003. Dexamethasone and ursodeoxycholic acid protect against the arrhythmogenic  
584 effect of taurocholate in an in vitro study of rat cardiomyocytes. *BJOG: An International  
585 Journal of Obstetrics and Gynaecology*. 110:467–474. doi:10.1046/j.1471-  
586 0528.2003.02273.x.
- 587 von Haehling, S., J.C. Schefold, E.A. Jankowska, J. Springer, A. Vazir, P.R. Kalra, A.  
588 Sandek, G.G. Fauler, T. Stojakovic, M. Trauner, P. Ponikowski, H.-D.D. Volk, W.  
589 Doehner, A.J.S.S. Coats, P.A. Poole-Wilson, and S.D. Anker. 2012. Ursodeoxycholic  
590 acid in patients with chronic heart failure: A double-blind, randomized, placebo-  
591 controlled, crossover trial. *Journal of the American College of Cardiology*. 59:585–592.  
592 doi:10.1016/j.jacc.2011.10.880.
- 593 Harrell FE, and M. Dupont. 2007. The Hmisc Package.

- 594 Huang, D.W., B.T. Sherman, and R.A. Lempicki. 2009a. Bioinformatics enrichment tools:  
595 paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids*  
596 *Research*. 37:1–13. doi:10.1093/nar/gkn923.
- 597 Huang, D.W., B.T. Sherman, and R.A. Lempicki. 2009b. Systematic and integrative analysis  
598 of large gene lists using DAVID bioinformatics resources. *Nature Protocols*. 4:44–57.  
599 doi:10.1038/nprot.2008.211.
- 600 Huby, A.C., G. Antonova, J. Groenendyk, C.E. Gomez-Sanchez, W.B. Bollag, J.A. Filosa,  
601 and E.J.B. de Chantemèle. 2015. Adipocyte-Derived Hormone Leptin Is a Direct  
602 Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and  
603 Cardiac Fibrosis. *Circulation*. 132:2134–2145.  
604 doi:10.1161/CIRCULATIONAHA.115.018226.
- 605 Ibrahim, E., I. Diakonov, D. Arunthavarajah, T. Swift, M. Goodwin, S. McIlvride, V. Nikolova,  
606 C. Williamson, and J. Gorelik. 2018. Bile acids and their respective conjugates elicit  
607 different responses in neonatal cardiomyocytes: role of Gi protein, muscarinic receptors  
608 and TGR5. *Scientific Reports*. 8:7110. doi:10.1038/s41598-018-25569-4.
- 609 Kawamata, Y., R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y.  
610 Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, and M. Fujino. 2003. A G protein-  
611 coupled receptor responsive to bile acids. *Journal of Biological Chemistry*. 278:9435–  
612 9440. doi:10.1074/jbc.M209706200.
- 613 Keitel, V., R. Reinehr, P. Gatsios, C. Rupprecht, B. Görg, O. Selbach, D. Häussinger, and R.  
614 Kubitz. 2007. The G-protein coupled bile salt receptor TGR5 is expressed in liver  
615 sinusoidal endothelial cells. *Hepatology*. 45:695–704. doi:10.1002/hep.21458.
- 616 Khalil, H., O. Kanisicak, V. Prasad, R.N. Correll, X. Fu, T. Schips, R.J. Vagnozzi, R. Liu, T.  
617 Huynh, S.-J. Lee, J. Karch, and J.D. Molkentin. 2017. Fibroblast-specific TGF- $\beta$ -  
618 Smad2/3 signaling underlies cardiac fibrosis. *Journal of Clinical Investigation*.  
619 127:3770–3783. doi:10.1172/JCI94753.
- 620 Kida, T., Y. Tsubosaka, M. Hori, H. Ozaki, and T. Murata. 2013. Bile acid receptor tgr5  
621 agonism induces no production and reduces monocyte adhesion in vascular endothelial  
622 cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 33:1663–1669.  
623 doi:10.1161/ATVBAHA.113.301565.
- 624 Lapenna, D., G. Ciofani, D. Festi, M. Neri, S.D. Pierdomenico, M.A. Giamberardino, and F.  
625 Cuccurullo. 2002. Antioxidant properties of ursodeoxycholic acid. *Biochemical*  
626 *Pharmacology*. 64:1661–1667. doi:10.1016/S0006-2952(02)01391-6.
- 627 Lindor, K.D., E.R. Dickson, W.P. Baldus, R.A. Jorgensen, J. Ludwig, P.A. Murtaugh, J.M.  
628 Harrison, R.H. Wiesner, M.L. Anderson, S.M. Lange, G. Lesage, S.S. Rossi, and A.F.  
629 Hofmann. 1994. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.  
630 *Gastroenterology*. 106:1284–1290. doi:10.1016/0016-5085(94)90021-3.
- 631 Masyuk, A.I., B.Q. Huang, B.N. Radtke, G.B. Gajdos, P.L. Splinter, T. v. Masyuk, S.A.  
632 Gradilone, and N.F. LaRusso. 2013a. Ciliary subcellular localization of TGR5  
633 determines the cholangiocyte functional response to bile acid signaling. *American*  
634 *Journal of Physiology-Gastrointestinal and Liver Physiology*. 304:G1013–G1024.  
635 doi:10.1152/ajpgi.00383.2012.

- 636 Masyuk, A.I., B.Q. Huang, B.N. Radtke, G.B. Gajdos, P.L. Splinter, T. v. Masyuk, S.A.  
637 Gradilone, and N.F. LaRusso. 2013b. Ciliary subcellular localization of TGR5  
638 determines the cholangiocyte functional response to bile acid signaling. *American*  
639 *Journal of Physiology-Gastrointestinal and Liver Physiology*. 304:G1013–G1024.  
640 doi:10.1152/ajpgi.00383.2012.
- 641 Miragoli, M., S.H. Sheikh Abdul Kadir, M.N. Sheppard, N. Salvarani, M. Virta, S. Wells, M.J.  
642 Lab, V.O. Nikolaev, A. Moshkov, W.M. Hague, S. Rohr, C. Williamson, J. Gorelik,  
643 S.H.S.A. Kadir, M.N. Sheppard, N. Salvarani, M. Virta, S. Wells, M.J. Lab, V.O.  
644 Nikolaev, A. Moshkov, W.M. Hague, S. Rohr, C. Williamson, J. Gorelik, S.H. Sheikh  
645 Abdul Kadir, M.N. Sheppard, N. Salvarani, M. Virta, S. Wells, M.J. Lab, V.O. Nikolaev,  
646 A. Moshkov, W.M. Hague, S. Rohr, C. Williamson, and J. Gorelik. 2011. A protective  
647 antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic  
648 fetal heart. *Hepatology*. 54:1282–1292. doi:10.1002/hep.24492.
- 649 Moreo, A., G. Ambrosio, B. de Chiara, M. Pu, T. Tran, F. Mauri, and S. v. Raman. 2009.  
650 Influence of Myocardial Fibrosis on Left Ventricular Diastolic Function. *Circulation:*  
651 *Cardiovascular Imaging*. 2:437–443. doi:10.1161/CIRCIMAGING.108.838367.
- 652 Moss, A.J., W. Zareba, W.J. Hall, H. Klein, D.J. Wilber, D.S. Cannom, J.P. Daubert, S.L.  
653 Higgins, M.W. Brown, and M.L. Andrews. 2002. Prophylactic Implantation of a  
654 Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. *New*  
655 *England Journal of Medicine*. 346:877–883. doi:10.1056/NEJMoa013474.
- 656 Mueller, M., A. Thorell, T. Claudel, P. Jha, H. Koefeler, C. Lackner, B. Hoesel, G. Fauler, T.  
657 Stojakovic, C. Einarsson, H.U. Marschall, and M. Trauner. 2015. Ursodeoxycholic acid  
658 exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in  
659 morbid obesity. *Journal of Hepatology*. 62:1398. doi:10.1016/J.JHEP.2014.12.034.
- 660 Mukaka, M.M. 2012. Statistics Corner: A guide to appropriate use of Correlation coefficient  
661 in medical research. 24. 69–71 pp.
- 662 Ovadia, C., J. Sajous, P.T. Seed, K. Patel, N.J. Williamson, G. Attilakos, F. Azzaroli, Y.  
663 Bacq, L. Batsry, K. Broom, R. Brun-Furrer, L. Bull, J. Chambers, Y. Cui, M. Ding, P.H.  
664 Dixon, M.C. Estiú, F.W. Gardiner, V. Geenes, M. Grymowicz, B. Günaydin, W.M.  
665 Hague, C. Haslinger, Y. Hu, U. Indraccolo, A. Juusela, S.C. Kane, A. Kebapcilar, L.  
666 Kebapcilar, K. Kohari, J. Kondrackienė, M.P.H. Koster, R.H. Lee, X. Liu, A. Locatelli,  
667 R.I.R. Macias, R. Madazli, A. Majewska, K. Maksym, J.A. Marathe, A. Morton, M.A.  
668 Oudijk, D. Öztekin, M.J. Peek, A.H. Shennan, R.M. Tribe, V. Tripodi, N. Türk  
669 Özterlemez, T. Vasavan, L.F.A. Wong, Y. Yinon, Q. Zhang, K. Zloto, H.-U. Marschall, J.  
670 Thornton, L.C. Chappell, and C. Williamson. 2021. Ursodeoxycholic acid in intrahepatic  
671 cholestasis of pregnancy: a systematic review and individual participant data meta-  
672 analysis. *The Lancet Gastroenterology & Hepatology*. doi:10.1016/S2468-  
673 1253(21)00074-1.
- 674 Pahor, M., R. Bernabei, A. Sgadari, G. Gambassi, P. Io Giudice, L. Pacifici, M.T. Ramacci,  
675 C. Lagrasta, G. Olivetti, and P. Carbonin. 1991. Enalapril prevents cardiac fibrosis and  
676 arrhythmias in hypertensive rats. *Hypertension*. 18:148–157.  
677 doi:10.1161/01.HYP.18.2.148.
- 678 Parés, A., L. Caballería, and J. Rodés. 2006. Excellent Long-Term Survival in Patients With  
679 Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid.  
680 *Gastroenterology*. 130:715–720. doi:10.1053/j.gastro.2005.12.029.

- 681 Pellicciari, R., A. Gioiello, A. Macchiarulo, C. Thomas, E. Rosatelli, B. Natalini, R. Sardella,  
682 M. Pruzanski, A. Roda, E. Pastorini, K. Schoonjans, and J. Auwerx. 2009. Discovery of  
683 6 $\alpha$ -Ethyl-23 (S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective  
684 Agonist for the TGR5 Receptor, a Novel Target for Diabesity. *Journal of Medicinal*  
685 *Chemistry*. 52:7958–7961. doi:10.1021/jm901390p.
- 686 Perbellini, F., S.A. Watson, M. Scigliano, S. Alayoubi, S. Tkach, I. Bardi, N. Quaife, C. Kane,  
687 N.P. Dufton, A. Simon, M.B. Sikkell, G. Faggian, A.M. Randi, J. Gorelik, S.E. Harding,  
688 and C.M. Terracciano. 2018. Investigation of cardiac fibroblasts using myocardial  
689 slices. *Cardiovascular Research*. 114:77–89. doi:10.1093/cvr/cvx152.
- 690 Perino, A., T.W.H. Pols, M. Nomura, S. Stein, R. Pellicciari, and K. Schoonjans. 2014. TGR5  
691 reduces macrophage migration through mTOR-induced C/EBP $\beta$  differential translation.  
692 *Journal of Clinical Investigation*. 124:5424–5436. doi:10.1172/JCI76289.
- 693 Pitoulis, F.G., S.A. Watson, F. Perbellini, and C.M. Terracciano. 2020. Myocardial slices  
694 come to age: an intermediate complexity in vitro cardiac model for translational  
695 research. *Cardiovascular Research*. 116:1275–1287. doi:10.1093/cvr/cvz341.
- 696 Pols, T.W.H., L.G. Noriega, M. Nomura, J. Auwerx, and K. Schoonjans. 2011. The bile acid  
697 membrane receptor TGR5 as an emerging target in metabolism and inflammation.  
698 *Journal of Hepatology*. 54:1263–1272. doi:10.1016/j.jhep.2010.12.004.
- 699 Rani, S., P.K. Sreenivasaiah, J.O. Kim, M.Y. Lee, W.S. Kang, Y.S. Kim, Y. Ahn, W.J. Park,  
700 C. Cho, and D.H. Kim. 2017. Tauroursodeoxycholic acid (TUDCA) attenuates pressure  
701 overload-induced cardiac remodeling by reducing endoplasmic reticulum stress. *PLOS*  
702 *ONE*. 12:e0176071. doi:10.1371/journal.pone.0176071.
- 703 Robinson, M.D., D.J. McCarthy, and G.K. Smyth. 2010. edgeR: a Bioconductor package for  
704 differential expression analysis of digital gene expression data. *Bioinformatics*. 26:139–  
705 140. doi:10.1093/bioinformatics/btp616.
- 706 Rodrigues, C.M.P., and C.J. Steer. 2001. The therapeutic effects of ursodeoxycholic acid as  
707 an anti-apoptotic agent. *Expert Opinion on Investigational Drugs*. 10:1243–1253.  
708 doi:10.1517/13543784.10.7.1243.
- 709 Sabbah, H.N., V.G. Sharov, M. Lesch, and S. Goldstein. 1995. Progression of heart failure:  
710 A role for interstitial fibrosis. *Molecular and Cellular Biochemistry*. 147:29–34.  
711 doi:10.1007/BF00944780.
- 712 Sato, H., A. Macchiarulo, C. Thomas, A. Gioiello, M. Une, A.F. Hofmann, R. Saladin, K.  
713 Schoonjans, R. Pellicciari, and J. Auwerx. 2008. Novel potent and selective bile acid  
714 derivatives as TGR5 agonists: Biological screening, structure-activity relationships, and  
715 molecular modeling studies. *Journal of Medicinal Chemistry*. 51:1831–1841.  
716 doi:10.1021/jm7015864.
- 717 Scardoni, G., G. Tosadori, S. Pratap, F. Spoto, and C. Laudanna. 2016. Finding the shortest  
718 path with PesCa: a tool for network reconstruction. *F1000Research*. 4:484.  
719 doi:10.12688/f1000research.6769.2.
- 720 Schafer, S., S. Viswanathan, A.A. Widjaja, W.-W. Lim, A. Moreno-Moral, D.M. DeLaughter,  
721 B. Ng, G. Patone, K. Chow, E. Khin, J. Tan, S.P. Chothani, L. Ye, O.J.L. Rackham,  
722 N.S.J. Ko, N.E. Sahib, C.J. Pua, N.T.G. Zhen, C. Xie, M. Wang, H. Maatz, S. Lim, K.


- 723 Saar, S. Blachut, E. Petretto, S. Schmidt, T. Putoczki, N. Guimarães-Camboa, H.  
724 Wakimoto, S. van Heesch, K. Sigmundsson, S.L. Lim, J.L. Soon, V.T.T. Chao, Y.L.  
725 Chua, T.E. Tan, S.M. Evans, Y.J. Loh, M.H. Jamal, K.K. Ong, K.C. Chua, B.-H. Ong,  
726 M.J. Chakaramakkil, J.G. Seidman, C.E. Seidman, N. Hubner, K.Y.K. Sin, and S.A.  
727 Cook. 2017. IL11 is a crucial determinant of cardiovascular fibrosis. *Nature*. 552:110.  
728 doi:10.1038/nature24676.
- 729 Schultz, F., A. Hasan, A. Alvarez-Laviada, M. Miragoli, N. Bhogal, S. Wells, C. Poulet, J.  
730 Chambers, C. Williamson, and J. Gorelik. 2016. The protective effect of  
731 ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting  
732 cardiac fibroblasts. *Progress in Biophysics and Molecular Biology*. 120:149–163.  
733 doi:10.1016/j.pbiomolbio.2016.01.003.
- 734 Shannon, P. 2003. Cytoscape: A Software Environment for Integrated Models of  
735 Biomolecular Interaction Networks. *Genome Research*. 13:2498–2504.  
736 doi:10.1101/gr.1239303.
- 737 Sweeney, M., B. Corden, and S.A. Cook. 2020. Targeting cardiac fibrosis in heart failure with  
738 preserved ejection fraction: mirage or miracle? *EMBO Molecular Medicine*. 12.  
739 doi:10.15252/emmm.201910865.
- 740 Szklarczyk, D., A.L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic,  
741 N.T. Doncheva, J.H. Morris, P. Bork, L.J. Jensen, and C. von Mering. 2019. STRING  
742 v11: protein–protein association networks with increased coverage, supporting  
743 functional discovery in genome-wide experimental datasets. *Nucleic Acids Research*.  
744 47:D607–D613. doi:10.1093/nar/gky1131.
- 745 Tanaka, A., J. Hirohara, Y. Nakanuma, H. Tsubouchi, and H. Takikawa. 2015. Biochemical  
746 responses to bezafibrate improve long-term outcome in asymptomatic patients with  
747 primary biliary cirrhosis refractory to UDCA. *Journal of Gastroenterology*. 50:675–682.  
748 doi:10.1007/s00535-014-0998-z.
- 749 Tarbit, E., I. Singh, J.N. Peart, and R.B. Rose’Meyer. 2019. Biomarkers for the identification  
750 of cardiac fibroblast and myofibroblast cells. *Heart Failure Reviews*. 24:1–15.  
751 doi:10.1007/s10741-018-9720-1.
- 752 Travers, J.G., F.A. Kamal, J. Robbins, K.E. Yutzey, and B.C. Blaxall. 2016. Cardiac fibrosis:  
753 The fibroblast awakens. *Circulation Research*. 118:1021–1040.  
754 doi:10.1161/CIRCRESAHA.115.306565.
- 755 Venero, J. v., M. Doyle, M. Shah, V.K. Rathi, J.A. Yamrozik, R.B. Williams, D.A. Vido, G.  
756 Rayarao, R. Benza, S. Murali, J. Glass, P. Olson, G. Sokos, and R.W.W. Biederman.  
757 2015. Mid wall fibrosis on CMR with late gadolinium enhancement may predict  
758 prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated  
759 cardiomyopathy—preliminary observations from a high-volume transplant centre. *ESC*  
760 *Heart Failure*. 2:150–159. doi:10.1002/ehf2.12041.
- 761 Wang, X.X., M.H. Edelstein, U. Gafter, L. Qiu, Y. Luo, E. Dobrinskikh, S. Lucia, L. Adorini,  
762 V.D. D’Agati, J. Levi, A. Rosenberg, J.B. Kopp, D.R. Gius, M.A. Saleem, and M. Levi.  
763 2016. G protein-coupled bile acid receptor TGR5 activation inhibits kidney disease in  
764 obesity and diabetes. *Journal of the American Society of Nephrology*. 27:1362–1378.  
765 doi:10.1681/ASN.2014121271.

- 766 Wang, Y.D., W.D. Chen, D. Yu, B.M. Forman, and W. Huang. 2011. The G-Protein-coupled  
767 bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response  
768 through antagonizing nuclear factor kappa light-chain enhancer of activated B cells  
769 (NF- $\kappa$ B) in mice. *Hepatology*. 54:1421–1432. doi:10.1002/hep.24525.
- 770 Warnes, G.R., B. Bolker, and T. Lumley. 2015. gtools: Various R Programming Tools. R  
771 package version 3.5.0. *CRAN*.
- 772 Watson, S.A., J. Duff, I. Bardi, M. Zabielska, S.S. Atanur, R.J. Jabbour, A. Simon, A. Tomas,  
773 R.T. Smolenski, S.E. Harding, F. Perbellini, and C.M. Terracciano. 2019. Biomimetic  
774 electromechanical stimulation to maintain adult myocardial slices in vitro. *Nature*  
775 *Communications*. 10:1–15. doi:10.1038/s41467-019-10175-3.
- 776 Watson, S.A., M. Scigliano, I. Bardi, R. Ascione, C.M. Terracciano, and F. Perbellini. 2017.  
777 Preparation of viable adult ventricular myocardial slices from large and small mammals.  
778 *Nature Protocols*. 12:2623–2639. doi:10.1038/nprot.2017.139.
- 779 Williamson, C., J. Gorelik, B.M. Eaton, M. Lab, M. de Swiet, and Y. Korchev. 2001. The bile  
780 acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-  
781 uterine fetal death in obstetric cholestasis. *Clinical Science*. 100:363–369.  
782 doi:10.1042/CS20000164.
- 783 Wright, P.T., N.K. Bhogal, I. Diakonov, L.M.K. Pannell, R.K. Perera, N.I. Bork, S.  
784 Schobesberger, C. Lucarelli, G. Faggian, A. Alvarez-Laviada, M. Zaccolo, T.J. Kamp,  
785 R.C. Balijepalli, A.R. Lyon, S.E. Harding, V.O. Nikolaev, and J. Gorelik. 2018.  
786 Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical  
787 Variation in  $\beta$ 2AR-cAMP Responsiveness in Murine Hearts. *Cell Reports*. 23:459–469.  
788 doi:10.1016/j.celrep.2018.03.053.
- 789 Xu, F., J. Wang, P. Wang, T. Hou, H. Zhou, Y. Zhao, J. Wang, Y. Liu, and X. Liang. 2022.  
790 Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4  
791 signaling. *European journal of pharmacology*. 917.  
792 doi:10.1016/J.EJPHAR.2022.174760.
- 793 Yang, Z., F. Xiong, Y. Wang, W. Gong, J. Huang, C. Chen, P. Liu, and H. Huang. 2016.  
794 TGR5 activation suppressed S1P/S1P2 signaling and resisted high glucose-induced  
795 fibrosis in glomerular mesangial cells. *Pharmacological Research*. 111:226–236.  
796 doi:10.1016/j.phrs.2016.05.035.
- 797 Ye, H.-L., J.-W. Zhang, X.-Z. Chen, P.-B. Wu, L. Chen, and G. Zhang. 2020.  
798 Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of  
799 autophagy. *Life Sciences*. 242:117175. doi:10.1016/j.lfs.2019.117175.
- 800 Yoneno, K., T. Hisamatsu, K. Shimamura, N. Kamada, R. Ichikawa, M.T. Kitazume, M. Mori,  
801 M. Uo, Y. Namikawa, K. Matsuoka, T. Sato, K. Koganei, A. Sugita, T. Kanai, and T.  
802 Hibi. 2013.  $\text{TGR}5$  signalling inhibits the production of pro-inflammatory  
803 cytokines by *in vitro* differentiated inflammatory and intestinal macrophages in Crohn's  
804 disease. *Immunology*. 139:19–29. doi:10.1111/imm.12045.
- 805 Yousefi, F., Z. Shabaninejad, S. Vakili, M. Derakhshan, A. Movahedpour, H. Dabiri, Y.  
806 Ghasemi, M. Mahjoubin-Tehran, A. Nikoozadeh, A. Savardashtaki, H. Mirzaei, and  
807 M.R. Hamblin. 2020. TGF- $\beta$  and WNT signaling pathways in cardiac fibrosis: Non-  
808 coding RNAs come into focus. *Cell Communication and Signaling*. 18:1–16.  
809 doi:10.1186/s12964-020-00555-4.

810

811 **Figures**


812 .



813

814 Figure 1


815



816

817 Figure 2

818




819

820 Figure 3

821

822




823

824

825 Figure 4


826



827

828 Figure 5


829



830

831 Figure 6

832



833

834 Figure 7

835

## 836 Figure legends

837 **Fig. 1: Construction of a fibrosis network.** **A** Gene ontology enrichment of IL-11 network.  
838 **B** Gene ontology (GO) enrichment of TGF- $\beta$  / WWP2 network. **C** A gene expression network  
839 constructed from published RNA-seq datasets and known interactors of GPBAR1. Circles  
840 represent genes belonging to the IL-11 co-expression network, diamonds represent genes  
841 belonging to the WWP2/ TGF- $\beta$  network, squares represent genes belonging to both pro-  
842 fibrotic networks. Two levels of the network are presented.

843

844 **Fig. 2. UDCA is antifibrotic in WT adult rat fibroblasts.** **A** Representative images of IL-11-  
845 treated WT rat FBs stained for  $\alpha$ SMA (M0851, Dako) green, Vimentin (PA1-16759, Thermo)  
846 red and DAPI blue. Culture conditions are displayed above each image. **B** Percentage of  
847 cells positive for  $\alpha$ SMA staining in response to UDCA. n= 3-16. **C** Representative images of  
848 FBs stained for Collagen I (ab34710, abcam) green, Vimentin (PA1-16759, Thermo) red and  
849 DAPI blue. Culture conditions are above each image. **D** Mean cell fluorescence of Collagen I  
850 staining in response to UDCA. n= 17-22. **E** Percentage of cells positive for  $\alpha$ SMA staining in  
851 response to INT-777. n= 9-19. **F** Representative Western blot and quantification of WT rat  
852 cell lysate probed for  $\alpha$ SMA and GAPDH (2118, Cell Signalling Technologies) in response to  
853 UDCA. n=4-13. **G** Representative Western blot and quantification of WT rat cell lysate  
854 probed for Collagen VI (ab6588, abcam) and GAPDH in response to UDCA. n=3-9. **H**  
855 Representative Western blot and quantification of WT rat lysate probed for Collagen I  
856 (ab34710) and GAPDH in response to UDCA. n= 4-5.

857

858 **Fig. 3. UDCA is antifibrotic in human dilated cardiomyopathy cardiac fibroblasts.** **A**  
859 Representative images of human DCM FB stained for  $\alpha$ SMA (M0851, Dako) green, Vimentin  
860 (PA1-16759, Thermo) red and DAPI blue. Culture conditions are displayed above each  
861 image. **B** Percentage of cells positive for  $\alpha$ SMA staining in response to UDCA. n= 3-13. **C**  
862 Representative images of FBs stained for Collagen I (ab34710, abcam) green, Vimentin  
863 (PA1-16759, Thermo) red and DAPI blue. Culture conditions are above each image. **D** Mean  
864 cell fluorescence of Collagen I staining in response to UDCA. n= 3-18. **E** Percentage of cells  
865 positive for  $\alpha$ SMA staining in response to INT-777. n= 12-21. **F** Representative Western blot  
866 and quantification of human DCM cell lysate probed for  $\alpha$ SMA and GAPDH (2118, Cell  
867 Signalling Technologies) in response to UDCA or INT-777. n= 3-5. **G** Representative  
868 Western blot and quantification of human DCM cell lysate probed for Collagen I (ab34710)  
869 and GAPDH in response to UDCA or INT-777. n=4-7.

870

871 **Fig. 4. UDCA reduces markers of fibrosis and improves contractile function of adult**  
872 **rat living myocardial slices.** **A** Representative images of IL-11-treated WT rat LMS stained  
873 for Collagen I (ab34710, abcam) green, Vimentin (PA1-16759, Thermo) grey and DAPI blue.  
874 Culture conditions are displayed above each image. **B** Percentage area of collagen I staining  
875 of LMS. n= 13-19, N= 3-7. **C** Representative Western blot and quantification of LMS lysate  
876 probed from Collagen I. n=5-6. **D** Representative contractile activity of WT rat LMS. Culture  
877 conditions are displayed above each trace. **E** Maximum contractility of LMS. n=8-14, N=6-8.  
878 **F** Contractility half-width. n= 11-12, N=6-8.

879

880 **Fig. 5. UDCA reduces markers of fibrosis in human living myocardial slices. A**  
881 Representative images of human LMS stained for Collagen I (ab34710, abcam) green,  
882 Vimentin (PA1-16759, Thermo) grey and DAPI blue. Culture conditions are displayed above  
883 each image. **B** Percentage area of collagen I staining of LMS. n= 12-17, N=3-7. **C**  
884 Representative contractile activity of LMS. Culture conditions are displayed above each  
885 trace. **D** Maximum contractility of human LMS normalised to average human donor  
886 contractility. n=8-10, N=3-7.

887

888 **Fig. 6. Reduction of fibrosis markers by UDCA is abolished in TGR5 KO mouse**  
889 **fibroblasts. A** Representative images of mouse FBs stained for  $\alpha$ SMA (M0851, Dako)  
890 green, Vimentin (PA1-16759, Thermo) red and DAPI blue. Culture conditions are displayed  
891 above each image. **B** Percentage of  $\alpha$ SMA positive FB in response to UDCA. n= 3-4. **C**  
892 Mean cell fluorescence of collagen I (ab34710, abcam). n=4-6. **D** Percentage of  $\alpha$ SMA  
893 positive FB in response to INT-777. n= 3-4. **E** Representative Western blot and  
894 quantification of mouse cell lysate probed for  $\alpha$ SMA and GAPDH (2118, Cell Signalling  
895 Technologies) in response to UDCA or INT-777. n=4-5. **F** Quantification of western blot for  
896 total ERK1/2 (4695, Cell Signalling Technologies) n= 3-5. **G** Representative Western blot  
897 and quantification of mouse cell lysate probed for ERK1/2 (4695, Cell Signalling  
898 Technologies), phosphorylated ERK1/2 (4370, Cell Signalling Technologies) and GAPDH in  
899 response to UDCA. n=5-6.

900

901 **Fig. 7. Identification of a cardiac fibrosis network in human fibroblasts A** Volcano plot  
902 of differentially expressed genes as determined by RNA-seq. Conditions compared were  
903 control (no treatment) vs 5ng/ml IL-11 stimulated human DCM FB. Significantly upregulated  
904 genes are marked in red, significantly down regulated genes are marked in blue. n=3. **B**  
905 Volcano plot of differentially expressed genes as determined by RNA-seq. Conditions  
906 compared were 5ng/ml IL-11 vs 1 $\mu$ M UDCA pre-treated stimulated human DCM FB.  
907 Significantly upregulated genes are marked in red, significantly down regulated genes are  
908 marked in blue. n=3. **C** Plot of significantly regulated genes of Human DCM FB. Log fold  
909 change in gene expression of IL-11 vs Control is plotted against UDCA vs IL-11. **D** Gene set  
910 enrichment analysis of IL-11 network. **E** Gene set enrichment analysis of WWP2 / TGF- $\beta$   
911 network. **F** Change in gene expression of fibrosis network generated in Fig. 1A due to  
912 treatment of human DCM cells with UDCA. Blue= reduced expression, Red= increased  
913 expression. Circles represent genes belonging to the IL-11 co-expression network,  
914 diamonds represent genes belonging to the WWP2/ TGF- $\beta$  network, squares represent  
915 genes belonging to both pro-fibrotic networks. Two levels of the network are presented.